# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mumtaz Mahal (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RE006-SYN-TD
- Date: 1631-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farzana Qureshi-Lindholm, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for first prenatal visit at 13 weeks in a fourteenth pregnancy: dating and nuchal translucency scan, prenatal tests, and a high-risk plan. **S**

## Objective

Hemoglobin: 10.1 g/dL (low); MCV: 76 fL (low); White blood cells: 8.6 10*3/uL; Platelets: 245 10*3/uL; Ferritin: 9 ng/mL (low); Hemoglobin A1c: 5.4%; Crown-rump length: 72 mm; Nuchal translucency: 1.7 mm; EPDS: 8. All results are synthetic.

BP 104/64 mmHg; pulse 84 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 58.6 kg; BMI 23.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12; Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children; Short interpregnancy interval: conception about five and a half months after her last birth; Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Folic acid 0.4 mg oral tablet, one tablet by mouth daily **S**
- Started: Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day **S**
- Started: Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Plan

- First prenatal visit: dating and nuchal translucency scan; blood count, ferritin, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture for asymptomatic bacteriuria; hemoglobin electrophoresis for microcytosis; hemoglobin A1c as an early diabetes screen; influenza vaccine; folic acid. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); USPSTF A and B Recommendations (2026); Guidelines for Vaccinating Pregnant Persons (2026) **S**
- Aneuploidy screening offered, with diagnostic testing available: cell-free DNA and the nuchal translucency measurement today, or chorionic villus sampling or amniocentesis; she chose cell-free DNA. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020) **S**
- Maternal-fetal medicine consultation for a fourteenth pregnancy at 37 with a short interpregnancy interval and anemia: surveillance, anemia treatment, placental assessment, delivery timing and place, and postpartum hemorrhage planning. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Practice Bulletin No. 183: Postpartum Hemorrhage (2017) **S**
- Iron deficiency anemia: ferrous sulfate 325 mg every other day; repeat blood count and ferritin in four weeks, with intravenous iron in the second trimester if she cannot tolerate oral iron or the hemoglobin does not rise; aim for hemoglobin of 11 g/dL or more before delivery. Guideline: Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021) **S**
- Preeclampsia prevention: aspirin 81 mg at bedtime from 13 weeks until delivery for two moderate risk factors (age 35 or older and a previous adverse pregnancy outcome); blood pressure and urine protein at every visit. Guideline: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021) **S**
- Detailed anatomy scan at 20 to 22 weeks with placental location; if the placenta is low-lying or covers the cervix, a repeat scan at 32 weeks and assessment for placenta accreta spectrum. Guideline: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Obstetric Care Consensus No. 7: Placenta Accreta Spectrum (2018) **S**
- Gestational diabetes: hemoglobin A1c today because she is of South Asian heritage with a BMI of 23 or more; one-hour glucose challenge at 24 to 28 weeks. Guideline: ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018) **S**
- Travel: travel is reasonable until about 36 weeks if the pregnancy stays uncomplicated; on long journeys walk every one to two hours, drink plenty, and wear compression stockings; carry her prenatal record; find maternity care where she stays; stay near the delivery hospital from 36 weeks. Guideline: ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018) **S**
- Postpartum hemorrhage risk assessment at intake and again in the third trimester and on admission for birth (grand multiparity and anemia raise her risk); delivery planned in a hospital with a blood bank, anesthesia, and an operating theatre. Guideline: Practice Bulletin No. 183: Postpartum Hemorrhage (2017); WHO recommendations for the prevention and treatment of postpartum haemorrhage (2012) **S**
- Mood: EPDS in each trimester, with support for the grief of having lost several children. Guideline: Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023) **S**
